RT Journal Article
SR Electronic
T1 5′ Flanking Variants of Resistin Are Associated With Obesity
JF Diabetes
JO Diabetes
FD American Diabetes Association
SP 1629
OP 1634
DO 10.2337/diabetes.51.5.1629
VO 51
IS 5
A1 Engert, James C.
A1 Vohl, Marie-Claude
A1 Williams, Scott M.
A1 Lepage, Pierre
A1 Loredo-Osti, J C.
A1 Faith, Janet
A1 Doré, Carole
A1 Renaud, Yannick
A1 Burtt, Noël P.
A1 Villeneuve, Amélie
A1 Hirschhorn, Joel N.
A1 Altshuler, David
A1 Groop, Leif C.
A1 Després, Jean-Pierre
A1 Gaudet, Daniel
A1 Hudson, Thomas J.
YR 2002
UL http://diabetes.diabetesjournals.org/content/51/5/1629.abstract
AB Diabetes and obesity have long been known to be related. The recently characterized adipocyte hormone resistin (also called FIZZ3/ADSF) has been implicated as a molecular link between impaired glucose tolerance (IGT) and obesity in mice. A search for sequence variants at the human resistin locus identified nine single-nucleotide polymorphisms (SNPs) but no coding variants. An investigation into the association of these SNPs with diabetes and obesity revealed two 5′ flanking variants (g.-537 and g.-420), in strong linkage disequilibrium, that are associated with BMI. In nondiabetic individuals from the Quebec City area and the Saguenay-Lac-St-Jean region of Quebec, the g.-537 mutation (allelic frequency = 0.04) was significantly associated with an increase in BMI (P = 0.03 and P = 0.01, respectively). When the data from these two populations were combined and adjusted for age and sex, both the g.-537 (odds ratio [OR] 2.72, 95% CI 1.28–5.81) and the g.-420 variants (1.58, 1.06–2.35) were associated with an increased risk for a BMI ≥30 kg/m2. In contrast, in case/control and family-based study populations from Scandinavia, we saw no effect on BMI with either of these promoter variants. No association was seen with diabetes in any of the population samples.